In the case of multi-center studies using an investigational drug or device, it is understood that the investigator will be receiving from the sponsor safety reports sent to the FDA from all centers participating in any study involving that drug or device. The investigator is expected to promptly forward these reports to the MHIRB using the Safety Reports Form (PDF).